Samuraciclib

Phase 2Small molecule

CCarrick Therapeutics Limited

Samuraciclib is one of 95 small molecule programs targeting Pancreas Ductal Adenocarcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pancreas Ductal AdenocarcinomaNot yet recruiting

Inoperable, Locally Advanced or Metastatic, ER-Positive Breast CancerRecruiting

Breast CancerCompleted

Pancreatic Ductal AdenocarcinomaRecruiting

Pancreas Ductal AdenocarcinomaPreclinical

Not yet recruiting

Inoperable, Locally Advanced or Metastatic, ER-Positive Breast CancerPreclinical

Recruiting

Breast CancerPhase 2

Completed

Pancreatic Ductal AdenocarcinomaPhase 1

Recruiting

Competition

Competitive Landscape

744 competitors in Breast Cancer

#DrugCompanyPhaseTrials

Samuraciclib

CCarrick Therapeutics Limited

Phase 2

3 2

Lexiscan

Astellas

Preclinical

1 3

Voltaren

Novartis

Preclinical

1 4

Zolymbus

AbbVie

Preclinical

1 5

Methylthioninium Chloride

PProvepharm SAS

Preclinical

3 6

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

3 7

Duragesic-100

CCephalon

Preclinical

2 8

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

2 9

Sporanox

SSebela Pharmaceuticals Development LLC

Preclinical

1 10

Tricor

JJagotec

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

Pancreatic Ductal Adenocarcinoma

NCT07645651

Q2 2029

PreclinicalRecruiting

Inoperable, Locally Advanced or Metastatic, ER-Positive Breast Cancer

NCT04802759

Q2 2030

PreclinicalNot yet recruiting

Pancreas Ductal Adenocarcinoma

NCT07665684

Clinical

Trials by Indication[1]

Breast Cancer3 trials

A Study of Samuraciclib in Combination With Fulvestrant in Metastatic or Locally Advanced Breast Cancer in Adult Participants

Completed·CCarrick Therapeutics Limited·Phase 2·NCT05963984·60 enrolled

A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer

Completed·CCarrick Therapeutics Limited·Phase 1/2·NCT05963997·49 enrolled

TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C)

Active, not recruiting· Pfizer logo

Pfizer·Phase 1/2·NCT06125522·11 enrolled

Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer1 trial

A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Breast Cancer (MORPHEUS-BREAST CANCER)

Recruiting· Roche logo

Roche·Preclinical·NCT04802759·316 enrolled

Pancreatic Ductal Adenocarcinoma1 trial

Phase 1b Window-of-Opportunity Study Evaluating CDK7 Inhibition in Patients With Localized Basal Pancreatic Cancer

Recruiting·UUniversity of Washington·Phase 1·NCT07645651·15 enrolled

Pancreas Ductal Adenocarcinoma1 trial

Phase Ib/II Study of Samuraciclib in Combination With Gemcitabine/Nab-Paclitaxel in Patients With Metastatic Basal-Like Pancreatic Cancer

Not yet recruiting·UUniversity Health Network, Toronto·Preclinical·NCT07665684·67 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Samuraciclib. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Samuraciclib compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Samuraciclib. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Carrick Therapeutics Limited company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: CCarrick Therapeutics Limited

Samuraciclib

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q2 2029

Q2 2030

Trials by Indication[1]

Breast Cancer3 trials

Inoperable, Locally Advanced or Metastatic, ER-positive Breast Cancer1 trial

Pancreatic Ductal Adenocarcinoma1 trial

Pancreas Ductal Adenocarcinoma1 trial

References

Drug Info

Quick Facts

Related News